The substitution with Sar at position 1 of angiotensin II resulted in a partial agonistic activity.

[Sar1, Ile8]-Angiotensin II acetate activates both the NADPH and NADH oxidases, and stimulates superoxide anion formation in vascular smooth muscle cells. [Sar1, Ile8]-Angiotensin II acetate has multiple effects on vascular smooth muscle, including contra

[Sar1, Ile8]-Angiotensin II 3TFA ([Sar1, Ile8]-Angiotensin II 3TFA (37827-06-8(free base))) is a peptide that has multiple effects on vascular smooth muscle.

[Sar1, Ile8]-Angiotensin II(3TFA) is a peptide that has multiple effects on vascular smooth muscle.

[Sar1, Ile8]-Angiotensin II (TFA) is a peptide compound that exerts various effects on vascular smooth muscle. These effects include the contraction of normal arteries as well as the hypertrophy or hyperplasia of cultured cells or diseased vessels.

(Sar1,Ile4,8)-Angiotensin II is a functionally selective agonist for the angiotensin II type 1 receptor (AT1R), enhancing insulin-stimulated signaling of the insulin receptor (IR) and glycogen synthesis. It boosts the insulin-induced phosphorylation of Akt and GSK3α/β [1].

Saralasin TFA ([Sar1,Ala8] Angiotensin II) is a synthetic octapeptide analog of angiotensin II, functioning as a competitive antagonist at angiotensin II receptors with a K i value of 0.32 nM for 74% of its binding sites, while also exhibiting partial agonist activity. It is utilized in the study of renovascular and renin-dependent (angiotensinogenic) hypertension [1] [3] [6].

Saralasin acetate is a Non-selective angiotensin II antagonist.